CervoMed neflamapimod Phase 2a nfvPPA biomarker data set for ISFTD 2026 oral session
CRVO•ISFTD oral session set for Phase 2a biomarker results
CervoMed set an ISFTD 2026 late-breaking oral session to disclose initial biomarker results from its Phase 2a neflamapimod trial in nfvPPA.
Data will be presented Oct. 11, 2026, shifting from an earlier abstract based on the first eight participants to results from at least 22.
Enrollment complete across U.S. and U.K. academic centers
Enrollment is complete at 25 participants across U.S. and U.K. academic centers, with the study assessing safety, drug exposure, and clinical effects.
Initial readout points to biological effects over 12 weeks
The initial readout points to measurable biological effects over 12 weeks, supporting continued evaluation in a disease with no approved therapies.
